When a patient presents with markedly elevated temperature and altered mental status, is it neuroleptic malignant syndrome or serotonin syndrome? If you do not have a medication list, some clinical signs may help. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 27 Drug-Induced Hyperthermic Syndromes in Psychiatry  

Psychopharmacology and Psychiatry Updates

Drug-Induced Hyperthermic Syndromes in Psychiatry

This episode discusses how to improve psychotropic drug adherence by targeting the reasons for nonadherence. It also discusses a 3-tiered approach to enhancing adherence, a patient questionnaire to evaluate the reasons for not taking medications, the top reasons for poor antipsychotic adherence, and the positive aspects of taking medications. Finally, it explains other approaches to improve adherence, such as simplifying the dosing regimen. Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Psychotropic Drug Adherence Improving Psychotropic Drug Adherence: Targeting Reasons for Nonadherence and the 3-Tiered Approach to Enhancing Adherence 

How to Improve Adherence: Targeting Reasons for Nonadherence

How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 27 Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System  

Esketamine: Postmarketing Safety Concerns

This episode discusses an algorithm for assessing adherence; the reasons for suboptimal adherence, including adverse drug reactions; measuring perceived side effects with the FIBSER scale; and how to help individuals communicate with providers about side effects. Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Psychotropic Drug Adherence Nonadherence: Adverse Drug Reactions, Measuring Perceived Side Effects With FIBSER, and Communication About Side Effects 

Nonadherence: Adverse Drug Reactions and Measuring Perceived Side Effects With FIBSER

Delirium has been frequently found in patients who test positive for COVID-19. It has additional features that we do not typically see in ordinary delirium. The critical question is: How do you manage these patients? Guest: Scott Beach, M.D. Interviewer: Wegdan Rashad, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Membership here Earn 0.5 CMEs: Neurocovid: Pharmacological recommendations for delirium associated with COVID-19 - Interview with Scott R. Beach, M.D.  

Neurocovid: Pharmacologic Recommendations for Delirium Associated With COVID-19

This episode discusses the assessment of adherence: Self-report, electronic medication monitoring systems, rating scales, medication possession ratio, questions for assessing medication adherence, and the recommended frequency of adherence monitoring.  Faculty: Martha Sajatovic, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Psychotropic Drug Adherence Assessing Adherence: Self-Report, Rating Scales, Medication Refills, Automated Pill-Taking Frequency Monitoring, Medication Routines, and Duration of Assessments  

How to Assess Psychotropic Drug Adherence

A new randomized trial suggests that the efficacy of antidepressants for the treatment of bipolar depression is no greater than placebo. This tips the meta-analytic balance scale, which already pointed in this direction. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 26 Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial 

Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD)

This podcast offers a discussion on catatonia and delirium as well as treatments for their co-occurrence. Treatments discussed include benzodiazepines, amantadine, and memantine. We also address the management of COVID-19 delirium with antipsychotics. Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Management of Delirium Special Considerations in Delirium: Catatonia and COVID-19 

Delirium, Catatonia, and COVID-19

Is psilocybin a potential treatment for major depression? There's certainly been a lot of press coverage, but to date, the reports are largely open trials in a variety of conditions, including OCD, substance use, PTSD, and patients with cancer and psychological distress. Against that backdrop, a randomized trial of psilocybin for major depression is an exciting new step. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 26 Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial 

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

This podcast features a discussion on the need to highlight anhedonia and anergia as core symptoms of depression. We also cover the clinical utility of MAOIs in treating patients with melancholic or biological depression and Parkinson's disease. Guest: Ken Gillman, M.D.; Interviewer: Wegdan Rashad, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Membership here Earn 0.5 CMEs: Dopamine and Depression: Clinical Considerations - Interview with Ken Gillman, M.D. 

Dopamine and Depression: Clinical Considerations

This podcast offers a discussion on the use of antipsychotics for managing delirium. Topics covered include: Choosing an antipsychotic, the advantages of IV haloperidol, different dosing strategies, and concerns regarding QT prolongation. We also examine chlorpromazine, olanzapine, quetiapine, and aripiprazole for managing delirium. Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Management of Delirium Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium 

Haloperidol, Chlorpromazine, and Atypical Antipsychotics for Managing Delirium

First-line treatments for child and adolescent depression are cognitive–behavioral therapy, interpersonal therapy, fluoxetine, and escitalopram. What works besides routine first-line approaches? This episode discusses options to consider: Pharmaceuticals, nutraceuticals, somatomotor techniques (e.g., yoga), and neuromodulatory tools (e.g., ECT and TMS). Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 25 New Somatic Treatments for Child and Adolescent Depression (Part 1)  

New Somatic Treatments for Child and Adolescent Depression

This episode discusses nonpharmacologic management strategies for delirium, such as the ones included in the ABCDE bundle. Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Management of Delirium Management of Delirium: Nonpharmacologic Strategies 

Management of Delirium: Nonpharmacologic Strategies

Are there any alternative medicine treatments that might be useful for your geriatric patients? We examine the evidence base for diet, herbal and nutritional supplements, and mind–body therapies for the prevention of dementia and the treatment of depression. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 0.5 CMEs: Quick Take Vol. 25 Emerging Complementary and Integrative Therapies for Geriatric Mental Health 

Emerging Complementary and Integrative Therapies for Geriatric Mental Health

This episode discusses the assessment of delirium. This includes: EEG and neurological exam, cognitive dysfunctions present in delirium, recommended testing, differential diagnoses, and the consequences of delirium. Faculty: Scott Beach, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about Premium Memberships here Earn 1 CME: Management of Delirium Delirium: Assessment, Consequences and Sequelae 

Delirium: Assessment, Consequences, and Sequelae

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

hubhopper

Psychopharmacology and Psychiatry Updates

hubhopper